Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report

Shahid Nadeem, Shireen Hashmat, Marissa J. Defreitas, Katherine D. Westreich, Ibrahim F. Shatat, David T. Selewski, Ali M. Onder, Myra Chiang, Donald J. Weaver, Julia Steinke, John Barcia, Joel Hernandez, Guillermo Hidalgo, Susan E. Ingraham, Carolyn L. Abitbol, Cynthia Pan, Larry A. Greenbaum

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Objectives Fetuses continue to be exposed to renin angiotensin system (RAS) blockers despite their known teratogenicity and a black box warning. We hypothesized that fetopathy from in utero exposure to RAS blockers has a broader spectrum of clinical manifestations than described previously and that there are a variety of clinical scenarios leading to such exposures. Study design This was a retrospective study performed through the Midwest Pediatric Nephrology Consortium. Cases of RAS blocker fetopathy were identified, with determination of renal and extrarenal manifestations, timing of exposure, and the explanation for the fetal exposure. Results Twenty-four cases were identified. RAS blocker exposure after the first trimester was associated with more severe renal manifestations. Chronic dialysis or kidney transplantation was required in 8 of 17 (47%) patients with RAS blocker exposure after the first trimester and 0 of 7 patients with exposure restricted to the first trimester (P = .05). Extrarenal manifestations, some not previously noted in the literature, included central nervous system anomalies (cystic encephalomalacia, cortical blindness, sensorineural hearing loss, arachnoid cysts) and pulmonary complications (pneumothorax, pneumomediastinum). RAS blocker exposure usually was secondary to absent or poor prenatal care or undiagnosed pregnancy. Conclusion RAS blocker fetopathy continues to be a cause of considerable morbidity, with more severe renal manifestations associated with exposure after the first trimester. A variety of significant extrarenal manifestations occur in these patients. Clinicians should emphasize the risk of fetopathy when prescribing RAS blockers to women of childbearing age.

Original languageEnglish (US)
Pages (from-to)881-885
Number of pages5
JournalJournal of Pediatrics
Volume167
Issue number4
DOIs
StatePublished - Oct 1 2015

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report'. Together they form a unique fingerprint.

  • Cite this

    Nadeem, S., Hashmat, S., Defreitas, M. J., Westreich, K. D., Shatat, I. F., Selewski, D. T., Onder, A. M., Chiang, M., Weaver, D. J., Steinke, J., Barcia, J., Hernandez, J., Hidalgo, G., Ingraham, S. E., Abitbol, C. L., Pan, C., & Greenbaum, L. A. (2015). Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report. Journal of Pediatrics, 167(4), 881-885. https://doi.org/10.1016/j.jpeds.2015.05.045